Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Krishna Murti

Krishna Murti

NIPER, India

Title: Comparative study of FDC Telmisartan+Amlodipine and individual Telmisartan and Amlodipine on Brain Natriuretic Peptide (BNP) and Cystatin - C in essential hypertensive patients

Biography

Biography: Krishna Murti

Abstract

Objectives: Comparative effect of fixed dose combination of Telmisartan+Amlodipine versus Telmisartan and Amlodipine alone on Brain Natriuretic Peptide (BNP), Cystatin - C and blood pressure in essential hypertensive patients.

Methods: A total of 90 patients, fulfilling inclusion and exclusion criteria were enrolled in the study after obtaining informed consent. Patients were randomized into three treatment groups i.e. Telmisartan 40 mg (Group A), Amlodipine 5 mg (Group B)  and low fixed dose combination of Telmisartan 40 mg +Amlodipine 5 mg (Group C) once daily for three  months. The systolic BP, Diastolic BP, BNP, Cystatin C were recorded at the start of the study and end of the study.              

Results: In the present study, significant reduction of mean systolic blood pressure (SBP) and mean diastolic blood pressure (DBP), BNP & Cystatin - C was seen in low fixed dose combination of Amlodipine 5 mg and Telmisartan 40 mg (Group C) compared to Telmisartan 40 mg and Amlodipine 5 mg mono-therapy. Some of adverse drug reactions (ADRs) were reported in Amlodipine mono-therapy group, like ankle oedema, headache, constipation and fatigue.

Discussion and Conclusion: Low fixed dose combination therapy appears to be a better therapeutic approach in relation of BP, BNP and Cystatin-C control than mono-therapy for primary hypertensive patients.